Parameter | All patients | Patients with complete covariate data | ||
---|---|---|---|---|
N | N | |||
Male sex, N (%) | 433 | 285 (65.8) | 297 | 197 (66.3) |
HLA-B27 positive, N (%) | 392 | 316 (80.6) | 297 | 240 (80.8) |
Age, years | 433 | 40.3 (11.0) | 297 | 39.5 (10.6) |
Symptom duration, years | 425 | 13.8 (9.8) | 297 | 13.5 (9.4) |
BASDAI | 369 | 4.2 (2.3) | 286 | 4.3 (2.3) |
ASDAS-CRP | 351 | 2.8 (1.1) | 276 | 2.9 (1.1) |
CRP (mg/l), median (IQR) | 365 | 8.0 (3.0; 11.0) | 278 | 8.0 (4.0; 12.0) |
Elevated CRP, N (%) | 364 | 147 (40.4) | 277 | 116 (41.9) |
BASFI | 373 | 3.1 (2.6) | 288 | 3.1 (2.5) |
BASMI | 375 | 2.2 (2.0) | 285 | 2.2 (2.5) |
mSASSS median (IQR) | 433 | 1.0 (0.0; 6.0) | 297 | 1.0 (0.0; 6.0) |
Mean (SD) | 6.6 (12.5) | 6.6 (12.6) | ||
Syndesmophytes present, N (%) | 433 | 148 (34.2) | 297 | 98 (33.0) |
EQ-5D | 370 | 65.1 (21.6) | 284 | 64.5 (21.5) |
Current peripheral arthritis, N (%) | 378 | 108 (28.6) | 289 | 82 (28.4) |
Current enthesitis, N (%) | 381 | 207 (54.3) | 288 | 171 (59.4) |
BMI 25–30, N (%) | 373 | 110 (29.5) | 287 | 84 (29.3) |
BMI > 30, N (%) | 373 | 58 (15.6) | 287 | 42 (14.6) |
On NSAID treatment, N (%) | 341 | 286 (83.9) | 277 | 236 (85.2) |
On TNFi treatment, N (%) | 433 | 163 (37.6) | 297 | 96 (32.3) |
Ever TNFi treatment, N (%) | 433 | 186 (43.0) | 297 | 116 (39.1) |
Years of TNFi treatment in treated patients | 163 | 2.1 (1.7) | 96 | 2.0 (1.6) |
Current smokers, N (%) | 366 | 140 (38.2) | 285 | 104 (36.5) |
Number exercise sessions per week | 366 | 2.0 (0.0; 4.0) | 286 | 2.0 (0.0; 4.0) |
Patients with different number of radiographic intervals, N (%) | 433 | 100 | 297 | 100 |
1 interval | 294 | 67.9 | 182 | 61.3 |
2 intervals | 92 | 21.2 | 76 | 25.6 |
3 intervals | 35 | 8.1 | 28 | 9.4 |
4 intervals | 11 | 2.5 | 10 | 3.4 |
5 intervals | 1 | 0.2 | 1 | 0.3 |